Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 53

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
 -   257,986   94,912   842,401 Others  40,414   43,128   147,231   103,500 TOTAL OTHER INCOME  107,760   465,527   408,641   1,397,479                  OPERATING EXPENSES                Sales and marketing  (551,569)  (1,245,456)  (1,700,691)  (1,535,821)Research and development  (14,876)  (10,442)  (39,572)  (30,115)General and administrative (including $1,065 and $1,006 of rental expenses to related party for the three months period ended September 30, 2025 and 2024, respectively, including $3,156 and $1,006 of rental expenses to related party for the nine months period ended September 30, 2025 and 2024, respectively)  (445,691)  (792,413)  (1,354,357)  (1,667,036)Fair value loss on investments in equity securities  -   (79,000)  (119,499)  (179,433)Provision for expected credit losses   (175,818)  (2,374)  (215,942)  (122,843)TOTAL OPERATING EXPENSES  (1,187,954)  (2,129,685)  (3,430,061)  (3,535,248)                 LOSS FROM OPERATIONS  (702,509)  (1,337,622)  (1,932,220)  (1,157,482)                 FINANCE COSTS  (6,482)  (6,193)  (16,270)  (15,334)                 LOSS BEFORE TAX  (708,991)  (1,343,815)  (1,948,490)  (1,172,816)                 Tax expense  -   (1,555)  -   (77,207)                 NET LOSS ATTRIBUTABLE TO